Morgan Cheatham

About

Morgan leads healthcare and life sciences investing for Breyer Capital. His work spans software, services, therapeutics, diagnostics, and AI. Prior to joining Breyer Capital, Morgan spent nearly a decade at Bessemer Venture Partners, where he helped lead the firm’s healthcare and life sciences investments and spearheaded early-stage investments in category-defining companies such as Abridge and Hinge Health. Morgan is also pursuing a fellowship in Clinical Genetics at Harvard/Boston Children’s. He serves as an Editorial Associate at NEJM AI and sits on the board of the Coalition for Health AI. His writing and research on clinical AI and genetic medicine have been published in leading biomedical journals such as Nature Medicine, NEJM AI, and PLOS. Morgan earned his B.S. in Computational Decision Sciences and M.D. from Brown University.

Source (opens in a new tab)